ATE171071T1 - Verfahren und zusammensetzungen zur verminderung von blutverlust - Google Patents

Verfahren und zusammensetzungen zur verminderung von blutverlust

Info

Publication number: ATE171071T1
Authority: AT; Austria
Prior art keywords: blood loss; compositions; methods; reducing blood; factor xiii
Prior art date: 1991-12-31

Application number

AT93902779T

Other languages

English (en)

Inventor

Bruce L A Carter

Martin William Edwards

Original Assignee

Zymogenetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-31

Filing date

1992-12-28

Publication date

1998-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25217802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE171071(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-12-28 Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc

1998-10-15 Application granted granted Critical

1998-10-15 Publication of ATE171071T1 publication Critical patent/ATE171071T1/de

Links

239000008280 blood Substances 0.000 title abstract 2
210000004369 blood Anatomy 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
108010071289 Factor XIII Proteins 0.000 abstract 2
229940012444 factor xiii Drugs 0.000 abstract 2
108010039627 Aprotinin Proteins 0.000 abstract 1
238000012084 abdominal surgery Methods 0.000 abstract 1
229960004405 aprotinin Drugs 0.000 abstract 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
210000000115 thoracic cavity Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT93902779T 1991-12-31 1992-12-28 Verfahren und zusammensetzungen zur verminderung von blutverlust ATE171071T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US81544391A	1991-12-31	1991-12-31

Publications (1)

Publication Number	Publication Date
ATE171071T1 true ATE171071T1 (de)	1998-10-15

Family

ID=25217802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93902779T ATE171071T1 (de)	1991-12-31	1992-12-28	Verfahren und zusammensetzungen zur verminderung von blutverlust

Country Status (8)

Country	Link
US (1)	US5607917A (de)
EP (1)	EP0624095B2 (de)
JP (1)	JPH07502734A (de)
AT (1)	ATE171071T1 (de)
AU (1)	AU3423493A (de)
CA (1)	CA2127107C (de)
DE (1)	DE69227042T3 (de)
WO (1)	WO1993012813A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5525335A (en) *	1992-04-21	1996-06-11	Ajinomoto Co., Inc.	Wound healing agent
EP1593389A1 (de) *	2000-05-10	2005-11-09	Novo Nordisk Health Care AG	Faktor VIIa und Factor XIII enthaltenden pharmazeutischen Verbindungen
ATE292625T1 (de)	2000-10-31	2005-04-15	Rensselaer Polytech Inst	8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
CA2438763A1 (en) *	2001-02-21	2002-09-06	Zymogenetics, Inc.	Blood coagulation factor xiii for treating platelet disorders
US7008926B2 (en) *	2001-02-22	2006-03-07	Zymogenetics Inc.	Blood coagulation factor XIII for treating platelet disorders
WO2005115442A1 (en) *	2004-05-25	2005-12-08	Novo Nordisk Health Care Ag	Use of coagulation factor xiii for treatment of post surgical bleedings
JP2008510476A (ja) *	2004-08-27	2008-04-10	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
JP5086093B2 (ja)	2004-11-23	2012-11-28	ジモジェネティクス、インコーポレイテッド	組換え型ヒトｘｉｉｉ因子の精製

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3931399A (en) †	1970-12-22	1976-01-06	Behringwerke Aktiengesellschaft	Process for isolating a fibrin-stabilizing factor
GB1575343A (en) *	1977-05-10	1980-09-17	Ici Ltd	Method for preparing liposome compositions containing biologically active compounds
US4235877A (en) *	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
DE3175036D1 (en) *	1980-10-02	1986-09-04	Hooper Trading Co Nv	A t-cell growth factor, and a process of producing the same
US4464355A (en) *	1981-03-26	1984-08-07	Hooper Trading Co.	Serum-free and mitogen-free T-cell growth factor and process for making same
US4684625A (en) *	1982-07-08	1987-08-04	Syntex (U.S.A.) Inc.	Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4522811A (en) *	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683199A (en) *	1983-01-31	1987-07-28	Sloan-Kettering Institute For Cancer Research	Interleukin-2 dependent cytotoxic T-cell clones
US4588578A (en) *	1983-08-08	1986-05-13	The Liposome Company, Inc.	Lipid vesicles prepared in a monophase
US4518584A (en) *	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
CA1237671A (en) *	1983-08-01	1988-06-07	Michael W. Fountain	Enhancement of pharmaceutical activity
US4565696A (en) *	1983-08-03	1986-01-21	The Regents Of The University Of California	Production of immunogens by antigen conjugation to liposomes
US4599227A (en) *	1983-11-07	1986-07-08	Wisconsin Alumni Research Foundation	Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4708861A (en) *	1984-02-15	1987-11-24	The Liposome Company, Inc.	Liposome-gel compositions
GB8405555D0 (en) *	1984-03-02	1984-04-04	Rees A D M	Macrophage activating factors
US4604377A (en) *	1984-03-28	1986-08-05	Cetus Corporation	Pharmaceutical compositions of microbially produced interleukin-2
US4636463A (en) *	1984-04-05	1987-01-13	Scripps Clinic And Research Foundation	Antibodies to human interleukin-2 induced by synthetic polypeptides
FR2562421B1 (fr) *	1984-04-09	1989-02-17	Sandoz Sa	Perfectionnements a la therapie par l'interleukine
BE902089A (fr) *	1984-04-09	1985-10-02	Sandoz Sa	Perfectionnements a la therapie par l'interleukine.
US4721612A (en) *	1984-04-12	1988-01-26	The Liposome Company, Inc.	Steroidal liposomes
EP0172007B1 (de) *	1984-08-10	1991-05-22	Syntex (U.S.A.) Inc.	Stabile Liposome mit wasserlöslichen Arzneimitteln
CA1260393A (en) *	1984-10-16	1989-09-26	Lajos Tarcsay	Liposomes of synthetic lipids
US4689222A (en) *	1985-01-18	1987-08-25	Mcmichael John	Methods and materials for alleviation of pain symptoms of malignant neoplasia
CA1256372A (en) *	1985-04-11	1989-06-27	Koichiro Miyazima	Process for producing liposome composition
US4663161A (en) *	1985-04-22	1987-05-05	Mannino Raphael J	Liposome methods and compositions
DE3687014T2 (de) *	1985-05-01	1993-04-01	Asahi Chemical Ind	Zum erkennen von tumoren faehige klonierte t-zelle und ein t-zellen-antigenrezeptor.
US4774085A (en) *	1985-07-09	1988-09-27	501 Board of Regents, Univ. of Texas	Pharmaceutical administration systems containing a mixture of immunomodulators
US4690915A (en) *	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
ES2039203T3 (es) *	1985-11-22	1993-09-16	Takeda Chemical Industries, Ltd.	Composicion de liposomas.
AU7128887A (en) *	1986-02-10	1987-08-25	Liposome Technology, Inc.	Controlled-release liposome delivery system
JPH0751496B2 (ja) *	1986-04-02	1995-06-05	武田薬品工業株式会社	リポソ−ムの製造法
AU7873187A (en) *	1986-08-08	1988-02-24	University Of Minnesota	Method of culturing leukocytes
US4781871A (en) *	1986-09-18	1988-11-01	Liposome Technology, Inc.	High-concentration liposome processing method
US4752425A (en) *	1986-09-18	1988-06-21	Liposome Technology, Inc.	High-encapsulation liposome processing method
ATE121776T1 (de) *	1986-09-19	1995-05-15	Zymogenetics Inc	Expression des biologisch aktiven faktors xiii.
US5017556A (en) *	1986-11-04	1991-05-21	Genentech, Inc.	Treatment of bleeding disorders using lipid-free tissue factor protein
EP0274219A3 (de) *	1986-12-04	1988-08-03	Takeda Chemical Industries, Ltd.	Interleukin-2 enthaltende Liposan-Zusammensetzung und Methode zu ihrer Herstellung
JPS63196520A (ja) *	1987-02-09	1988-08-15	Hoechst Japan Kk	潰瘍性大腸炎治療剤
US4808151A (en) *	1987-04-27	1989-02-28	E. I. Du Pont De Nemours And Company	Simplified method for the preparation of human lymphokine activated killer cells
WO1989005149A1 (en) *	1987-12-03	1989-06-15	The Liposome Company, Inc.	Methyl cellulose pharmaceutical composition
AU2925789A (en) *	1987-12-17	1989-07-19	Browning's Clinical Pathology Services Limited	Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
FR2624741B1 (fr) *	1987-12-21	1991-06-28	Pasteur Institut	Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
JPH01216939A (ja) *	1988-02-24	1989-08-30	Hoechst Japan Kk	末熟児頭蓋内出血阻止剤
JPH03503844A (ja) *	1988-04-15	1991-08-29	リサーチ　コーポレーシヨン　テクノロジーズ　インコーポレーテツド	Ｌａｋ細胞サイトトキシン
EP0366770B1 (de) *	1988-05-16	1994-02-09	Vestar, Inc.	An hormone gekoppelte liposome
US5204447A (en) *	1988-11-14	1993-04-20	Zymogenetics, Inc.	Purification of factor xiii
US5047406A (en) *	1989-12-06	1991-09-10	Warner-Lambert Co.	Substituted cyclohexanols as central nervous system agents

1992
- 1992-12-28 AU AU34234/93A patent/AU3423493A/en not_active Abandoned
- 1992-12-28 WO PCT/US1992/011241 patent/WO1993012813A1/en not_active Ceased
- 1992-12-28 DE DE69227042T patent/DE69227042T3/de not_active Expired - Lifetime
- 1992-12-28 CA CA002127107A patent/CA2127107C/en not_active Expired - Lifetime
- 1992-12-28 AT AT93902779T patent/ATE171071T1/de not_active IP Right Cessation
- 1992-12-28 JP JP51191893A patent/JPH07502734A/ja active Pending
- 1992-12-28 EP EP93902779A patent/EP0624095B2/de not_active Expired - Lifetime
1995
- 1995-05-31 US US08/456,018 patent/US5607917A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69227042T2 (de)	1999-05-27
CA2127107A1 (en)	1993-07-08
AU3423493A (en)	1993-07-28
WO1993012813A1 (en)	1993-07-08
CA2127107C (en)	2007-06-19
DE69227042D1 (de)	1998-10-22
EP0624095A1 (de)	1994-11-17
US5607917A (en)	1997-03-04
EP0624095B2 (de)	2005-07-20
DE69227042T3 (de)	2006-07-27
EP0624095B1 (de)	1998-09-16
JPH07502734A (ja)	1995-03-23

Legal Events

Date	Code	Title	Description
1999-03-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
Saad et al.	1992	Surgical treatment of chronic fissure-in-ano: a prospective randomised study
ES2161229T3 (es)	2001-12-01	Microesferas bioterapeuticas revestidas con celulas.
DE69013833D1 (de)	1994-12-08	Zusammensetzung und methode zur verhütung von verklebungen zwischen körpergewebe.
DE68905438D1 (de)	1993-04-22	Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.
DE60039978D1 (de)	2008-10-02	Substitutions-infusionflüssigkeit und zitratanticoagulation
ATE240730T1 (de)	2003-06-15	Verwendung von levobupivacaine in gesichtschirugie
ATE240731T1 (de)	2003-06-15	Verwendung von levobupivacaine in der pediatrischen chirurgie
ATE368455T1 (de)	2007-08-15	Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE171071T1 (de)	1998-10-15	Verfahren und zusammensetzungen zur verminderung von blutverlust
KR900002802A (ko)	1990-03-23	면역억제제로서의 트랜스글루타미나제의 용도
DE69924483D1 (de)	2005-05-04	Kombinationstherapie zur behandlung von tumoren
Mulkey	1976	Outpatient treatment of hemophiliacs for dental extractions
ES2157208T3 (es)	2001-08-16	Composicion y procedimiento para la reduccion del riesgo de hipotension.
DE69431430D1 (de)	2002-10-31	Faktor XIII zur Behandlung von Hautwunden
GR3000751T3 (en)	1991-10-10	Tpa-containing medical composition and use thereof
RU93029510A (ru)	1996-06-10	Способ противоишемической защиты тканей конечности
DK1007085T3 (da)	2002-05-13	Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
AU2002225994A1 (en)	2002-05-15	Use of blood coagulation factor xiii for treating haemophilia
DE60139574D1 (de)	2009-09-24	Kombination von aktiviertem factor viia und fibrinogen und verwendung zur behandlung von blutung
ATE72397T1 (de)	1992-02-15	Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
DE69218544D1 (de)	1997-04-30	Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
Kim et al.	1971	A Case of Congenital Metatarsus Varus Feduced by Surgical Method.
UA9703A (uk)	1996-09-30	Антипротеіназний засіб
Kalteziotis et al.	1992	The influence of the type of anaesthesia on the incidence of deep vein thrombosis after total hip replacement
Heller et al.	1992	The behaviour of factor XIII in surgical patients in tropical West Nigeria